Vexim SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vexim SA Acquires System for Mixing and Injecting Orthopedic Cement
Vexim SA announced the acquisition of a technological system in the injection of orthopedic cement for its development in vertebroplasty. Thanks to its SpineJack implant, Vexim already had technology for the mini-invasive treatment of vertebral compression fractures, notably enabling the anatomic restoration of fractured vertebra and the reestablishment of the spinal column's balance. Thanks to the acquisition of a system for mixing and injecting orthopedic cement that complements the Company's SpineJack technology, Vexim is expanding its presence in the field of vertebroplasty, which currently represents around half of mini-invasive procedures in the treatment of vertebral compression. This new system will thus allow surgery to be performed on indications where priority is given to stabilizing the fracture and eliminating pain by injecting cement into the vertebra.
Latest Developments for Vexim SA
- Vexim SA obtains FDA approval to market masterflowTM injection system in the United States
- Vexim announces launch of private placement for about 5 million euros
- Vexim to commence U.S. sales and marketing operations with appointment of regional sales director
- Vexim announces positive preliminary results of Spinejack and Medtronic balloon comparison
- Share this
- Digg this